{"id":20267954,"updated":"2026-09-28T15:09:44Z","additionalIndexing":"2841","affairType":{"abbreviation":"Fra.","id":14,"name":"Fragestunde. Frage"},"author":{"councillor":{"code":10838,"gender":"m","id":10838,"name":"Vontobel Erich","officialDenomination":"Vontobel"},"faction":{"abbreviation":"Fraktion V","code":"V","id":4,"name":"Fraktion der Schweizerischen Volkspartei"},"type":"author"},"deposit":{"council":{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N"},"date":"2026-09-23T00:00:00Z","legislativePeriod":52,"session":"5215"},"descriptors":[],"drafts":[{"consultation":{"resolutions":[{"category":{"id":3,"name":"Normal"},"council":{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N"},"date":"2026-09-28T00:00:00Z","text":"Mündliche Beantwortung der Frage","type":82}]},"federalCouncilProposal":{},"index":0,"links":[],"preConsultations":[],"references":[],"relatedDepartments":[{"abbreviation":"EDI","id":4,"name":"Departement des Innern","leading":true}],"states":[{"date":"\/Date(1790114400000+0200)\/","id":202,"name":"Eingereicht"},{"date":"\/Date(1790546400000+0200)\/","id":229,"name":"Erledigt"}],"texts":[]}],"language":"de","priorityCouncils":[{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N","priority":1}],"relatedAffairs":[],"roles":[{"councillor":{"code":10838,"gender":"m","id":10838,"name":"Vontobel Erich","officialDenomination":"Vontobel"},"faction":{"abbreviation":"Fraktion V","code":"V","id":4,"name":"Fraktion der Schweizerischen Volkspartei"},"type":"author"}],"shortId":"26.7954","state":{"id":229,"name":"Erledigt","doneKey":"0","newKey":1},"texts":[{"type":{"id":5,"name":"Eingereichter Text"},"value":"<p>In der Pfizer-Zulassungsstudie traten ab sieben Tagen nach Dosis 2 ein schwerer Covid-19-Fall in der Impfgruppe und drei in der Placebogruppe auf. Das vordefinierte Erfolgskriterium wurde nicht erreicht; das Ergebnis war nicht statistisch signifikant. Am 19.02.2021 fragte Swissmedic zudem, ob lediglich eine Person der Placebogruppe hospitalisiert worden sei.&nbsp;<br>Welche damaligen RCT-Daten belegen, dass bei der Zulassung ein Schutz vor schweren Verläufen nachgewiesen war?<\/p>"},{"type":{"id":1,"name":"Titel des Geschäftes"},"value":"Comirnaty: Nachweis des Schutzes vor schweren Covid-19-Verläufen bei der Zulassung"}],"title":"Comirnaty: Nachweis des Schutzes vor schweren Covid-19-Verläufen bei der Zulassung"}